P. Kiewe

A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines (2008)

Schmid, P., Kühnhardt, D., Kiewe, P., Lehenbauer-Dehm, S., Schippinger, W., Greil, R., ...

Background: Proteasome inhibitors are a novel class of compounds entering clinical trials as a method to increase tumour sensitivity to standard chemotherapy. This phase I/II trial was carried out to...

Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma (2006)

Kiewe, P, Bechrakis, NE, Schmittel, A, Ruf, P, Lindhofer, H, Thiel, E, ...

Background: Metastatic uveal melanoma has a poor prognosis and limited therapeutic options. Proteoglycans are involved in tumor cell invasion and metastatic behavior. The mAbB5 stains a chondroitin...

Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma (2006)

Kiewe, P., Bechrakis, N. E., Schmittel, A., Ruf, P., Lindhofer, H., Thiel, E., ...

Background: Metastatic uveal melanoma has a poor prognosis and limited therapeutic options. Proteoglycans are involved in tumor cell invasion and metastatic behavior. The mAbB5 stains a chondroitin...

Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma (2006)

Kiewe, P., Bechrakis, N. E., Schmittel, A., Ruf, P., Lindhofer, H., Thiel, E., ...

Background: Metastatic uveal melanoma has a poor prognosis and limited therapeutic options. Proteoglycans are involved in tumor cell invasion and metastatic behavior. The mAbB5 stains a chondroitin...